Dr. Colette Shen discusses unmet needs in recurrent head and neck cancer, highlighting a novel treatment study aimed at improving patient outcomes.
Videos
An expert discusses how maintenance lurbinectedin benefits patients across subgroups, including those with liver metastases, and may be considered for patients with brain metastases after radiation therapy, while emphasizing the importance of patient counseling about continued chemotherapy expectations.
An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab therapy at progression, as the maintenance approach doesn't change subsequent treatment sequencing.
An expert discusses findings from the Paloma-3 study, emphasizing how subcutaneous amivantamab improves patient-reported outcomes and quality of life, reinforcing a growing oncology focus on treatment experience, tolerability, and patient-centered care alongside clinical efficacy.
FDA's new guidance clarifies overall survival data collection in clinical trials, emphasizing long-term follow-up, subgroup analysis, and trial design considerations.
Dr Harpreet Singh explores the FDA's new guidance on overall survival as a clinical trial endpoint, addressing its implications and challenges in oncology.
A groundbreaking study reveals the potential of alternative donors in bone marrow transplantation, paving the way for improved patient outcomes and innovative practices.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Innovative research transforms bone marrow transplantation, enhancing outcomes with mismatched and haploidentical donors, expanding access to life-saving treatments.
A new study reveals that optimized donor search algorithms significantly enhance transplant outcomes for patients, even with alternative donor sources.
A new study explores strategies to enhance survival rates for patients facing challenges in finding bone marrow donors, advocating for quicker alternative options.
Discover key advancements in breast cancer treatment and the ongoing challenges in access, drug resistance, and patient quality of life.
Experts emphasize the need for regulatory alignment between the FDA and EMA to streamline radiopharmaceutical development and enhance patient access.
Lowell B. Anthony, MD, discusses the potential benefits of cabozantinib for patients for different types of patients with neuroendocrine tumors.
Discover groundbreaking advancements in breast cancer treatment, focusing on targeted therapies, immunotherapy, and personalized care strategies for improved patient outcomes.
Dr. Shane Dormady shares innovative cancer treatment strategies, emphasizing hope and precision medicine to empower young adult patients facing diagnoses.
Sarah Premji, MD, discusses recent advancements in the breast cancer treatment landscape.
Julie Brahmer, MD, and David P. Carbone, MD, PhD, share insights on managing toxicities of immune checkpoint inhibitor therapies in non–small cell lung cancer.
Dr Harpreet Singh discusses the FDA's new guidance on radiopharmaceutical dosing, emphasizing dose justification and data integration for patient safety.
Dr Harpreet Singh discusses the FDA's draft guidance on radiopharmaceutical dosing, highlighting significant shifts in dose limits and safety monitoring for clinical trials.
An expert discusses how moving lurbinectedin to earlier in treatment is justified because 40% to 50% of patients with small cell lung cancer (SCLC) never receive second-line therapy due to rapid disease progression, making proactive treatment essential.
An expert discusses efforts to improve the tolerability and delivery of the MARIPOSA regimen, highlighting subcutaneous amivantamab from the Paloma studies and proactive skin care strategies from the Cocoon study as key advances in enhancing patient experience, adherence, and clinical outcomes.
An expert discusses how lurbinectedin maintenance therapy causes primarily hematologic toxicities but has a low discontinuation rate (6.2%), making it suitable for most patients with good performance status and adequate blood count recovery.
Harpreet Singh, MD, former FDA director, discusses the FDA's new draft guidance on radiopharmaceutical dosing and its relation to Project Optimus.
Dr. Gerrina Ruiter discusses zongertinib's promising efficacy in treating HER2-mutant NSCLC, highlighting its unique effectiveness against brain metastases.
Innovative advancements in cell therapy enhance NK cells for solid tumors, aiming for effective treatments while prioritizing patient safety and clinical success.
Chandler H. Park, MD, discusses NCCN treatment regimens for patients with metastatic bladder cancer.
Discover how El Camino Health's multidisciplinary approach enhances cancer care for younger adults, featuring collaboration among diverse medical specialists.
Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with brain metastases.
Katy Rezvani, MD, PhD, discusses advancements in CAR-NK cell therapy, focusing on enhancing antitumor efficacy while ensuring safety through precise gene editing techniques.